Related Experiment Video

Updated: Jul 5, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Novel mechanistic concept of platelet inhibition

Alexander B Sigalov1

  • 1University of Massachusetts Medical School, Department of Pathology, 55 Lake Avenue North, Worcester, MA 01655, USA. Alexander.Sigalov@umassmed.edu

Expert Opinion on Therapeutic Targets
|May 16, 2008
PubMed

Insights

New research reveals the Signaling Chain Homooligomerization (SCHOOL) model for inhibiting platelet activation. This discovery offers novel therapeutic targets for developing safer antithrombotic drugs, reducing bleeding risks in patients.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Molecular Biology

Background:

  • Platelet activation by collagen is key in thrombotic diseases like heart attack and stroke.
  • Current antithrombotic drugs reduce cardiovascular events but cause dangerous bleeding.
  • Uncontrolled hemorrhage remains a significant side effect of existing antithrombotics.

Purpose of the Study:

  • To explore a novel mechanistic concept for platelet inhibition.
  • To understand the mechanism of glycoprotein VI (GPVI) signaling.
  • To identify new therapeutic targets for antithrombotic strategies.

Main Methods:

  • Review of innovative mechanistic concepts in platelet inhibition.
  • Focus on the central platelet collagen receptor, GPVI.
  • Analysis of GPVI signaling pathways.

Main Results:

  • Introduction of the Signaling Chain Homooligomerization (SCHOOL) model for GPVI signaling.
  • Identification of new therapeutic targets for GPVI inhibition.
  • Development of novel antithrombotic pharmacological approaches.

Conclusions:

  • The SCHOOL model provides a new understanding of GPVI signaling.
  • This mechanistic insight enables the development of targeted antithrombotic therapies.
  • Novel platelet inhibitors have been invented based on the SCHOOL model, potentially improving antithrombotic safety.
Abstract

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...